BridgeBio Pharma (NASDAQ:BBIO) executives used a BofA healthcare conference appearance in Las Vegas to reiterate confidence in the commercial trajectory of Attruby and outline expectations for three potential...
- Phase 3 CALIBRATE primary results were presented in an oral presentation at the 2026 ECE, demonstrating the rapid and durable benefit of encaleret across key clinical parameters in ADH1 - All...
-Acoramidis increased sTTR early and significantly reduced intra-individual sTTR variability versus placebo (p
PALO ALTO, Calif., May 08, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genetic...
BridgeBio Pharma (NASDAQ:BBIO) reported first-quarter 2026 results highlighted by continued growth for ATTRUBY and increased investment to support three anticipated launches, while also announcing a new...
$194.5 million in total first quarter revenues, comprised of $180.6 million of U.S. Attruby® net product revenue, with strong prescribing growth and patient persistence driving continued commercial momentum...
Barchart Research What to Expect from BBIO Earnings BBIO Generated May 6, 2026 Current Price $68.09 EPS Estimate $$-0.70 Consensus Rating Strong Buy Average Move 2.86% BridgeBio Pharma: The Commercial...
PALO ALTO, Calif., May 06, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genetic...
- The approval of Beyonttra in Brazil is based on positive results from the Phase 3 ATTRibute-CM study, in which acoramidis demonstrated the most rapid benefit seen in any Phase 3 study of ATTR-CM to date,...